Drug Profile
RGA 1512
Latest Information Update: 14 May 2019
Price :
$50
*
At a glance
- Originator Targeted Genetics
- Developer Targeted Genetics Corporation
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Myeloid leukaemia
Most Recent Events
- 09 May 2019 C3J Therapeutics has merged with AmpliPhi Biosciences Corporation to form Armata Pharmaceuticals
- 01 Jul 1998 No-Development-Reported for Myeloid leukaemia in USA (Unknown route)
- 17 May 1995 Preclinical development for Myeloid leukaemia in USA (Unknown route)